# This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.

> **NCT07520318** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shenzhen Oculgen Biomedical Technology Co., Ltd.** · enrollment: 255 (estimated)

## Conditions studied

- Adults With Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** bispecific anti-VEGF and anti-complement

## Key facts

- **NCT ID:** NCT07520318
- **Lead sponsor:** Shenzhen Oculgen Biomedical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-03-29
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07520318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07520318, "This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07520318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*